The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent

about

The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent

Item

http://www.wikidata.org/entity/Q57816676

description

scientific article published on 09 October 2018

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2018

@uk

name

The Antitumor Activity of Comb ...... Inhibitors Is Model-Dependent

@en

The Antitumor Activity of Comb ...... Inhibitors Is Model-Dependent

@nl

type

Item

label

The Antitumor Activity of Comb ...... Inhibitors Is Model-Dependent

@en

The Antitumor Activity of Comb ...... Inhibitors Is Model-Dependent

@nl

prefLabel

The Antitumor Activity of Comb ...... Inhibitors Is Model-Dependent

@en

The Antitumor Activity of Comb ...... Inhibitors Is Model-Dependent

@nl

P1476

The Antitumor Activity of Comb ...... Inhibitors Is Model-Dependent

@en

P2093

Anne Tourette

http://www.w3.org/2001/XMLSchema#string

Aurore Bourguignon

http://www.w3.org/2001/XMLSchema#string

Chloé Grasselly

http://www.w3.org/2001/XMLSchema#string

Doriane Mathe

http://www.w3.org/2001/XMLSchema#string

Eva Laure Matera

http://www.w3.org/2001/XMLSchema#string

Laurent Serre

http://www.w3.org/2001/XMLSchema#string

Morgane Denis

http://www.w3.org/2001/XMLSchema#string

Nolan Talhi

http://www.w3.org/2001/XMLSchema#string

P2860

Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy

Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy

Nivolumab plus ipilimumab in advanced melanoma.

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.

The blockade of immune checkpoints in cancer immunotherapy

Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice.

Opdivo (Nivolumab): Second PD-1 Inhibitor Receives FDA Approval for Unresectable or Metastatic Melanoma

FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.

P304

2100

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FIMMU.2018.02100

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

C Dumontet

Lars Jordheim

P577

2018-10-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30356816

http://www.w3.org/2001/XMLSchema#string

P921

chemotherapy

P932

6190749

http://www.w3.org/2001/XMLSchema#string